20
Participants
Start Date
October 3, 2024
Primary Completion Date
October 31, 2026
Study Completion Date
December 31, 2026
Recombinant von Willebrand Factor
Recombinant von Willebrand Factor is a drug that is currently FDA approved to treat patients with certain types of von Willebrand Disease. In the current trial it will be used to treat ECMO patients who have acquired von Willebrand syndrome.
RECRUITING
UVA Hospital, Charlottesville
University of Virginia
OTHER